Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide has a half-life of roughly one week, meaning the body naturally reduces its concentration by around half every seven days after the last dose. That is not a fast exit. Full clearance from your system typically takes four to five weeks, and no supplement, drink or protocol meaningfully speeds that process up. If you are trying to stop Wegovy or manage how it leaves your body, the most useful thing you can do is understand the timeline and talk to the prescriber who oversees your treatment, because stopping mid-course without clinical input carries its own risks. These are prescription-only medicines, and decisions about stopping, pausing or switching should involve the clinician who assessed you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, demonstrated that the weight-loss and appetite-suppressing effects of semaglutide 2.4mg reversed substantially within weeks to months of stopping treatment, which is itself the clearest evidence that the drug is clearing from the body. That reversal is driven by the same pharmacokinetics that make Wegovy effective in the first place: semaglutide binds tightly to albumin in the bloodstream, which extends its half-life to around seven days. After a single missed or final dose, concentrations fall by half each week. By four weeks, circulating levels are very low. By five weeks, the drug is effectively cleared for most people.
There is no clinical trial or regulatory guidance that identifies an intervention to shorten this window. The semaglutide overview at nume has more detail on how the medicine works inside the body, but the short version is that its extended half-life is a deliberate design feature, not a problem to engineer around. You can learn more about why Wegovy stays active for a full week between injections and what that means for the clearance curve.
Searches for how to flush semaglutide or Wegovy out of your system often land on suggestions involving high water intake, activated charcoal, specific diets or exercise protocols. The evidence base for any of these accelerating clearance is absent. Semaglutide is not stored in fat tissue in a way that mobilising fat would release it. It is not primarily excreted in urine such that drinking more water would speed elimination. It is metabolised through standard proteolytic pathways and cleared gradually regardless of what else you eat or drink.
Staying well hydrated and eating regularly during the clearance period is genuinely sensible, but for practical reasons: GI side effects can linger during the first week or two after stopping, and keeping fluid and food intake steady reduces the discomfort. That is different from flushing the drug out. If you are asking about specific clearance approaches or want the broader picture of how long semaglutide stays in your system, those pages go deeper into the mechanisms.
One thing our prescribers hear fairly often is that people stopping Wegovy feel a kind of urgency about wanting it gone quickly, often because of a side effect or a planned medical procedure. That urgency is entirely understandable. But the biology does not bend to it, and knowing that can actually be reassuring: a consistent, predictable clearance timeline means you can plan around it.
There are specific circumstances where knowing when semaglutide will be out of your system has real clinical importance. Before any surgical procedure, your anaesthetist and surgical team need to know you have been taking a GLP-1 medicine, because gastric emptying can remain altered even after stopping. The NHS England guidance on weight-management injections is explicit on this point: inform your healthcare team, including the anaesthetist, before any planned surgery. The timing of your last dose relative to the procedure date should be discussed with them directly.
Pregnancy planning is another situation where timing matters. The Wegovy page at nume notes that semaglutide is not recommended during pregnancy, breastfeeding or when trying to conceive. The MHRA advises using effective contraception during treatment and for a period after the last dose before attempting to conceive. Specific timelines for your circumstances should come from your GP or prescriber, not from a general guide. If you are considering switching between medicines rather than stopping entirely, the comparison of semaglutide formulations and their respective timelines may also be relevant.
People managing type 2 diabetes alongside weight treatment have additional considerations when stopping any GLP-1 medicine, as blood glucose control can shift. Again, this is a conversation for your prescriber rather than something to manage independently.
The week or two after stopping Wegovy can bring a noticeable shift in appetite. Most people find hunger returns before weight does, and that experience can feel abrupt. The NHS information on semaglutide side effects and stopping guidance confirms that effects reverse as the drug clears, which is expected rather than alarming. Eating regular meals with adequate protein and fibre during this window can make appetite changes more manageable.
GI symptoms that were present on treatment, such as nausea or slower digestion, may shift direction as clearance progresses. For most people these resolve. If symptoms worsen significantly or you experience severe abdominal pain, seek medical attention promptly and mention that you have recently been taking semaglutide.
If you are pausing rather than stopping permanently, and you are considering restarting or exploring alternatives, the weight-loss treatment overview at nume explains the options available through a private prescription. Our prescribers carry out a fresh clinical review before any course of treatment, including restarting after a break. For anyone who has not yet begun treatment and is researching what stopping would look like before they start, that is a sensible question to raise during an initial consultation at our treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.